EcoDrugPlus

Amyloid-Beta A4 Protein-Like

Ensembl ID : ENSOKIG00005032646
Gene Symbol: LOC109871012
2 Cross references
199 Possible Orthologues:

Amyloid-Beta A4 Protein-Like

Ensembl ID : ENSOKIG00005029332
Gene Symbol: LOC109869985
3 Cross references
199 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSOKIG00005049638
Gene Symbol: AR
3 Cross references
207 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSOKIG00005049803
Gene Symbol: AR
3 Cross references
206 Possible Orthologues:

Androgen Receptor-Like

Ensembl ID : ENSOKIG00005048692
Gene Symbol: LOC109883122
2 Cross references
200 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSOKIG00005050987
Gene Symbol: AGTR1
3 Cross references
193 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSOKIG00005015789
Gene Symbol: AGTR1
1 Cross references
193 Possible Orthologues:

Angiotensin Ii Receptor, Type 2

Ensembl ID : ENSOKIG00005026971
Gene Symbol: AGTR2
1 Cross references
181 Possible Orthologues:

Anti-Apoptotic Protein Nr13

Ensembl ID : ENSOKIG00005034494
Gene Symbol: LOC109885084
3 Cross references
124 Possible Orthologues:

Anti-Apoptotic Protein Nr13-Like

Ensembl ID : ENSOKIG00005023553
Gene Symbol: LOC116374888
3 Cross references
124 Possible Orthologues:

Antithrombin-Iii-Like

Ensembl ID : ENSOKIG00005026341
Gene Symbol: LOC109889078
3 Cross references
195 Possible Orthologues:

Apelin Receptor B-Like

Ensembl ID : ENSOKIG00005010472
Gene Symbol: LOC109885708
3 Cross references
171 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).